Press release
Global Acute Ischemic Stroke Diagnosis and Treatment Market’s Future Lies in MRI, Expected to Reach US$1.9 bn by 2020
Acute ischemic strokes imply the loss of brain function created by the lack of blood supply to the brain. The most common cause of acute ischemic strokes is the formation of atherosclerosis plaques that narrow or block blood vessels. Another major cause is the formation of blood clots in the arteries to the brain.Download Free Exclusive Sample of this Report: http://bit.ly/2dnz6Cg
According to the report, the primary factor responsible for the current growth rate of the global acute ischemic stroke diagnosis and treatment market is the increasing prevalence of the disease. This market’s growth rate is further supported by the developments that modern medicine and medical devices are allowing in it. Due to the incorporation of these developments, the success rate of surgeries is improving the world over, causing a higher growth rate to show over the given forecast period.
The report’s users can gain deep insights into the acute ischemic stroke diagnosis and treatment market based on its segmented analysis, through the categories of surgery type and diagnostic type. According to surgery type, this market is segmented into endovascular mechanical thrombectomy, angioplasty, and carotid endarterectomy.
Based on surgery type, this market was dominated by carotid endaterectomy in 2013, owing to easier availability, shorter length of treatment time, and a greater success rate. This segment could, however, experience a fall in market shares due to the presence of major side effects.
Based on diagnostic type, this market is segmented into nuclear imaging, cerebral angioplasty, ultrasound, magnetic resonance imaging, computed tomography, and others. Although CT has dominated the global acute ischemic stroke diagnosis and treatment market so far, it is expected to be steadily replaced by the MRI method, owing to higher efficiency and lower costs.
The report also provides a detailed geographical review of the acute ischemic stroke diagnosis and treatment market by segmenting it into the major zones of North America, Asia Pacific, Europe, and the Rest of the World.
Owing to a high patient pool and the presence of highly advanced technologies, this market was dominated by North America in 2013. The second-largest region in the acute ischemic stroke diagnosis and treatment market is Europe, owing to the rapidly increasing geriatric population across this region.
Browse Research Report: http://bit.ly/2dnNsCY
Meanwhile, Asia Pacific is showing the fastest growth rate among all major regions. This is attributed to the surging healthcare industry, the growing population density, and the rising rates of awareness and healthcare expenditures.
The key players in the global acute ischemic stroke diagnosis and treatment market are Hitachi, Ltd., GE Healthcare, Johnson & Johnson, Stryker Corporation, Penumbra, Inc., Philips Healthcare, Siemens Healthcare, Abbott Laboratories, and Covidien plc.
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Acute Ischemic Stroke Diagnosis and Treatment Market’s Future Lies in MRI, Expected to Reach US$1.9 bn by 2020 here
News-ID: 367247 • Views: …
More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during…

North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the…

Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016.
The global dental membrane and bone graft substitutes market is expected to…

Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period.
By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment…
More Releases for Acute
Acute Lymphoblastic Leukemia Therapeutics Market Size, Acute Lymphoblastic Leuke …
Acute Lymphoblastic Leukemia Therapeutics Market Dynamics are clarified by an in-depth review of facts on current and emerging trends. To understand a resource, the paper uses Porter's five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers provided by various agents, competitive strength, and promising new businesses. precious. Furthermore, the study covers numerous firms' Acute Lymphoblastic Leukemia Therapeutics research data, benefit, gross margin,…
Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market
Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but…
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H …
ReportsWorldwide has announced the addition of a new report title Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Renal Failure (ARF) (Acute Kidney Injury) clinical trials scenario. This report provides top line data relating to…
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to…
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Tri …
ReportsWorldwide has announced the addition of a new report title Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to…
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth…